Onterris adopts poison pill, stock drops 34%

What happened

Onterris, Inc., a management consulting services company, announced on August 5, 2026, that its board had adopted a shareholder rights plan, commonly known as a "poison pill." The company declared a dividend of one preferred share purchase right for each share of common stock outstanding as of August 17, 2026.

The rights will initially trade attached to the common shares. They will separate and become exercisable only if a person or group acquires beneficial ownership of 15% or more of Onterris' common stock (the "Distribution Date"). Each right then entitles the holder (other than the acquiring person) to buy one one-thousandth of a share of newly created Series B Preferred Stock at an exercise price of $105.00 per fraction.

The rights expire on August 4, 2027, unless earlier redeemed or exchanged by the board. The board can redeem the rights for $0.001 per right at any time before a person becomes an acquiring person.

Onterris also filed a Certificate of Designations for the Series B Preferred Stock with the Delaware Secretary of State and issued a press release about the plan.

Details of the rights plan

The rights agreement was entered into with Computershare Trust Company, N.A., as rights agent. Key features of the plan:

"Flip-in" event: If a person or group becomes an acquiring person (15% owner), each right (except those held by the acquirer) becomes exercisable for common shares worth twice the exercise price, effectively diluting the acquirer's stake.

"Flip-over" event: If the company is later acquired in a merger or sells 50% or more of its assets after an acquiring person appears, each right allows the holder to buy shares of the acquiring company at a 50% discount.

The board may exchange the rights (except those held by the acquirer) for one common share per right at any time after an acquiring person appears.

Certain existing large holders are "grandfathered" and not automatically treated as acquiring persons, but they lose that status if they increase their stake or fall below 15%.

The board can exempt specific persons or transactions from triggering the plan, provided it does so before that person becomes an acquiring person.

Stock price reaction

On the day of the announcement, Onterris' stock fell 33.85%, closing at $14.97, down from the prior close of $22.63. Trading volume was 2,222,018 shares, more than three times the average volume of 662,133. The filing does not explain why the stock dropped, nor does it state the reason the board adopted the poison pill.

What this means

A shareholder rights plan is a defensive measure companies use to deter unwanted takeover attempts. By giving existing shareholders (other than the would-be acquirer) the right to buy discounted shares, the plan makes a hostile bid more expensive and dilutes the acquirer's voting power.

The specific terms here target a 15% ownership threshold — a common trigger for poison pills. The exercise price of $105 per one-thousandth of a preferred share effectively values each right's target at $105,000 per full preferred share, though the rights themselves have a nominal redemption price of $0.001.

The plan expires in one year unless renewed. Companies often adopt poison pills without a specific threat being disclosed. The 8-K filing fulfills the SEC requirement to report material agreements (Item 1.01), modifications to security holder rights (Item 3.03), amendments to the charter (Item 5.03), and other events (Item 8.01 for the press release).

The Certificate of Designations created a new class of preferred stock (Series B) that the rights represent fractional interests in. This preferred stock is designed to mimic common shares in dividends and liquidation, so the rights primarily affect voting and control rather than economic value.

What happens next: If no person crosses the 15% threshold before August 4, 2027, the rights will expire worthless. The board can also redeem the rights at any time before a trigger, effectively ending the plan.